Laureate Pharma, Inc. has entered into a cGMP contract manufacturing agreement with Enobia Pharma, a biotechnology company developing an enzyme replacement therapy for the treatment of hypophosphatasia. Under the agreement, Laureate will produce Enobia’s fusion protein for treatment of hypophosphatasia, a rare, and potentially fatal metabolic bone disease characterized by skeletal hypomineralization. Terms of the agreement were not disclosed. “We are delighted by the confidence ...